血清CEA、CYFRA21-1及TK1联合早期诊断非小细胞肺癌研究
|
摘要
目的探讨血清癌胚抗原(CEA)、细胞角蛋白片段19抗原21-1(CYFRA21-1)及胸苷激酶(TK1)在非小细胞肺癌早期诊断中的临床意义。方法选择2016年1月至2018年1月收治的非小细胞肺癌患者97例为观察组;另选择2016年1月至2018年1月收治的肺部良性疾病患者60例作为对照组。采用免疫放射分析法测定CEA含量,采用免疫放射分析法测定CYFRA21-1含量,采用点印迹免疫酶化学发光法测定TK1含量。比较2组血清CEA、CYFRA21-1和TK1水平变化,不同临床分期和淋巴结转移血清CEA、CYFRA21-1和TK1水变化。结果观察组血清CEA、CYFRA21-1和TK1水平高于对照组,差异有统计学意义(P<0.05);Ⅲ～Ⅳ期血清CEA、CYFRA21-1和TK1水平高于Ⅰ～Ⅱ期,差异有统计学意义(P<0.05);淋巴结转移血清CEA、CYFRA21-1和TK1水平高于无淋巴结转移,差异有统计学意义(P<0.05);CEA、CYFRA21-1和TK1联合诊断灵敏度和特异度高于单项检测。结论血清CEA、CYFRA21-1和TK1联合诊断非小细胞肺癌早期具有重要意义,值得临床借鉴。
Objective To investigate the clinical significance of serum carcinoembryonic antigen(CEA), cytokeratin fragment 19 antigen 21-1(CYFRA21-1) and thymidine kinase(TK1) in the early diagnosis of non-small cell lung cancer(NSCLC).Methods Ninety-seven patients with NSCLC who were admitted and treated in our hospital from January 2016 to January 2018 were enrolled as observation group,and the 60 patients with benign pulmonary diseases who were admitted and treated in our hospital from January 2016 to January 2018 were enrolled as control group. The content of CEA and CYFRA21-1 was determined by immunoradiometric assay respectively. The content of TK1 was determined by dot blot immunochromatography. The changes in levels of serum CEA, CYFRA21-1 and TK1 were compared between the two groups, and the above indicators. The changes of serum levels of CEA, CYFRA21-1 and TK1 were observed and compared in patients with different clinical stages and lymph node metastasis. Results The serum levels of CEA, CYFRA21-1 and TK1 in observation group were significantly higher than those in control group(P<0.05). The serum levels of CEA, CYFRA21-1 and TK1 in patients at stage Ⅲ～Ⅳ were significantly higherthan those of patients at stage Ⅰ～Ⅱ(P<0.05). The serum levels of CEA, CYFRA21-1 and TK1 in patients with lymph node metastasis were significantly higher than those pf patients without lymph node metastasis(P<0.05). The diagnostic sensitivity and specificity of CEA, CYFRA21-1 and TK1 combination detection were higher than those by single index detection.Conclusion The combination detection of serum levels of CEA, CYFRA21-1 and TK1 is of great significance in early diagnosis of NSCLS, which is worthy of clinical reference.
Objective To investigate the clinical significance of serum carcinoembryonic antigen(CEA), cytokeratin fragment 19 antigen 21-1(CYFRA21-1) and thymidine kinase(TK1) in the early diagnosis of non-small cell lung cancer(NSCLC).Methods Ninety-seven patients with NSCLC who were admitted and treated in our hospital from January 2016 to January 2018 were enrolled as observation group,and the 60 patients with benign pulmonary diseases who were admitted and treated in our hospital from January 2016 to January 2018 were enrolled as control group. The content of CEA and CYFRA21-1 was determined by immunoradiometric assay respectively. The content of TK1 was determined by dot blot immunochromatography. The changes in levels of serum CEA, CYFRA21-1 and TK1 were compared between the two groups, and the above indicators. The changes of serum levels of CEA, CYFRA21-1 and TK1 were observed and compared in patients with different clinical stages and lymph node metastasis. Results The serum levels of CEA, CYFRA21-1 and TK1 in observation group were significantly higher than those in control group(P<0.05). The serum levels of CEA, CYFRA21-1 and TK1 in patients at stage Ⅲ～Ⅳ were significantly higherthan those of patients at stage Ⅰ～Ⅱ(P<0.05). The serum levels of CEA, CYFRA21-1 and TK1 in patients with lymph node metastasis were significantly higher than those pf patients without lymph node metastasis(P<0.05). The diagnostic sensitivity and specificity of CEA, CYFRA21-1 and TK1 combination detection were higher than those by single index detection.Conclusion The combination detection of serum levels of CEA, CYFRA21-1 and TK1 is of great significance in early diagnosis of NSCLS, which is worthy of clinical reference.
引文
1 Vyfhuis MAL,Burrows WM,Bhooshan N,et al.Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced,Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys,2018,101:445-452.
2 Torigoe H,Yamamoto H,Sakaguchi M,et al.Tumor-suppressive effect of LRIG1,a negative regulator of ErbB,in non-small cell lung cancer harboring mutant EGFR.Carcinogenesis,2018,39:719-727.
3 林铖,姜傥.液体活检技术在非小细胞肺癌患者EGFR-TKI继发耐药中的应用.检验医学,2016,31:835-843.
4 陈巧巧,孙一奎,王峰.联合检测外周血游离LUNXmRNA、SCC和β2-MG对非小细胞肺癌的早期诊断价值.中国免疫学杂志,2016,32:720-721.
5 苏光建,肖振州,肖燕萍,等.血清miR-223的表达及联合CEA、CYFRA21-1对非小细胞肺癌的诊断价值.标记免疫分析与临床,2016,23:857-861.
6 高洋,张启知,凌建华,等.非小细胞肺癌患者血清CYfra21-1、CEA、NSE手术前后的水平变化及意义.检验医学与临床,2018,13:213-216.
7 陈波,吴国荣,杨万勇,等.HE4、CYFRA21—1和TPS联合检测对非小细胞肺癌的早期诊断价值.实用医学杂志,2016,32:3721-3724.
8 芦珂.CYFRA21-1、Pentraxin-3、ProGRP对非小细胞肺癌的诊断价值.中国实验诊断学,2016,20:378-380.
9 杨浩,许军生,曾湖,等.CEA、CYFRAZ1-1、NSE、SCC联合检测对肺癌诊断及组织分型的应用研究.河北医药,2018,40:2926-2929,2933.
10 杜军华,乔洪源,尹宜发.血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响.肿瘤防治研究,2016,43:137-140.
11 陈树林,张妮,肖倩,等.血清ADAM8、CEA与血浆m2-PK三者单独及联合检测在非小细胞肺癌早期诊断中的价值.标记免疫分析与临床,2016,23:248-251.
12 王秋波,施雪峰,李巍,等.CEA、CYFRA21-1和CA125联合检测对非小细胞肺癌患者预后水平的评估价值.实用癌症杂志,2016,31:1601-1604.
13 季禹乔,孙明忠,朱晖,等.血清miRNA-21与肿瘤标志物CEA、CYFRA21-1、NSE对早期非小细胞肺癌的诊断价值.中国实验诊断学,2017,21:576-581.
14 鲁丹,万彦彬,赖馨,等.血清CEA、NSE、CYFRA21-1水平与非小细胞肺癌病理分期的相关性.中国实验诊断学,2016,20:912-914.
15 王彬,李国锋,王健,等.血清 TK1水平检测在非小细胞肺癌诊断中的应用.国际检验医学杂志,2016,37:2563-2565.
16 黄志宇,李建成,郑步宏,等.血清胸苷激酶1水平与晚期非小细胞肺癌含培美曲塞方案疗效的关系分析.临床肿瘤学杂志,2017,22:792-796.
2 Torigoe H,Yamamoto H,Sakaguchi M,et al.Tumor-suppressive effect of LRIG1,a negative regulator of ErbB,in non-small cell lung cancer harboring mutant EGFR.Carcinogenesis,2018,39:719-727.
3 林铖,姜傥.液体活检技术在非小细胞肺癌患者EGFR-TKI继发耐药中的应用.检验医学,2016,31:835-843.
4 陈巧巧,孙一奎,王峰.联合检测外周血游离LUNXmRNA、SCC和β2-MG对非小细胞肺癌的早期诊断价值.中国免疫学杂志,2016,32:720-721.
5 苏光建,肖振州,肖燕萍,等.血清miR-223的表达及联合CEA、CYFRA21-1对非小细胞肺癌的诊断价值.标记免疫分析与临床,2016,23:857-861.
6 高洋,张启知,凌建华,等.非小细胞肺癌患者血清CYfra21-1、CEA、NSE手术前后的水平变化及意义.检验医学与临床,2018,13:213-216.
7 陈波,吴国荣,杨万勇,等.HE4、CYFRA21—1和TPS联合检测对非小细胞肺癌的早期诊断价值.实用医学杂志,2016,32:3721-3724.
8 芦珂.CYFRA21-1、Pentraxin-3、ProGRP对非小细胞肺癌的诊断价值.中国实验诊断学,2016,20:378-380.
9 杨浩,许军生,曾湖,等.CEA、CYFRAZ1-1、NSE、SCC联合检测对肺癌诊断及组织分型的应用研究.河北医药,2018,40:2926-2929,2933.
10 杜军华,乔洪源,尹宜发.血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响.肿瘤防治研究,2016,43:137-140.
11 陈树林,张妮,肖倩,等.血清ADAM8、CEA与血浆m2-PK三者单独及联合检测在非小细胞肺癌早期诊断中的价值.标记免疫分析与临床,2016,23:248-251.
12 王秋波,施雪峰,李巍,等.CEA、CYFRA21-1和CA125联合检测对非小细胞肺癌患者预后水平的评估价值.实用癌症杂志,2016,31:1601-1604.
13 季禹乔,孙明忠,朱晖,等.血清miRNA-21与肿瘤标志物CEA、CYFRA21-1、NSE对早期非小细胞肺癌的诊断价值.中国实验诊断学,2017,21:576-581.
14 鲁丹,万彦彬,赖馨,等.血清CEA、NSE、CYFRA21-1水平与非小细胞肺癌病理分期的相关性.中国实验诊断学,2016,20:912-914.
15 王彬,李国锋,王健,等.血清 TK1水平检测在非小细胞肺癌诊断中的应用.国际检验医学杂志,2016,37:2563-2565.
16 黄志宇,李建成,郑步宏,等.血清胸苷激酶1水平与晚期非小细胞肺癌含培美曲塞方案疗效的关系分析.临床肿瘤学杂志,2017,22:792-796.